title: [Second-line chemotherapy for advanced pancreatic cancer].
abstract: Many investigators have attempted to reach a consensus, though with limited evidence available, on second-line chemotherapy for advanced pancreatic cancer. Specifically, treatment consists of gemcitabine-based regimens and 5-FU-based regimens. The regimen that is not used for first-line chemotherapy will be used as second-line chemotherapy. In Japan, S-1 is frequently used in 5-FU-based regimens. When the FOLFIRINOX regimen is used as first-line chemotherapy, gemcitabine is recommended as second-line chemotherapy. On the other hand, when nab-PTX/gemcitabine is used as first-line chemotherapy, S-1 is recommended as second-line chemotherapy.
authors.affiliation: Dept. of Medical Oncology, Hirosaki University Graduate School of Medicine.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sato
authors.forename: Kensuke
authors.initials: K
authors.lastname: Saito
authors.forename: Takenori
authors.initials: T
authors.lastname: Takahata
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*